Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-? activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A?.
Source:http://linkedlifedata.com/resource/pubmed/id/21352079
